Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

Intellia had already paused dosing in trials of nex-z in transthyretin amyloidosis after the patient was hospitalized due to a serious adverse event.

NEW ORLEANS -- Innovations in lipid lowering get a major chance to shine, and potentially move the needle in cardiometabolic ...

Nex-z is the most closely watched drug in Intellia’s development pipeline. The company said in September that it planned to ...

Scientists at Georgia State University have used CRISPR gene editing to restore an ancient enzyme humans lost millions of years ago potentially reversing the buildup of uric acid that causes gout.

How do regulators address concerns in the court of evidentiary decision making -- and of public opinion -- surrounding ...

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.

Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.